Evidence map›Paper›PMID 42401950›Full record

ArticleAIDS research and therapy2026

Brief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Uganda.

Angella Nabakooza, Sharon Kitibwakye Nakamanya, Eva Agnes Laker, Elizabeth Katana, Noela Owarwo, Isaac Lwanga, Barbara Castelnuovo, Mohammed Lamorde, Freddy Kitutu Eric

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angella NabakoozaDepartment of Pharmacy, Makerere University School of Health Sciences, PO Box 7072, Kampala, Uganda. angellanabakooza@gmail.com.ORCID http://orcid.org/0009-0007-2065-748X
Sharon Kitibwakye NakamanyaDepartment of Pharmacy, Makerere University School of Health Sciences, PO Box 7072, Kampala, Uganda.ORCID http://orcid.org/0009-0002-5784-9497
Eva Agnes LakerInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Elizabeth KatanaInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Noela OwarwoInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Isaac LwangaInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Barbara CastelnuovoInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Mohammed LamordeInfectious Disease Institute (IDI), Makerere University College of Health Sciences, Kampala, Uganda.
Freddy Kitutu EricDepartment of Pharmacy, Makerere University School of Health Sciences, PO Box 7072, Kampala, Uganda.ORCID http://orcid.org/0000-0003-2277-9572

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoosted atazanavir (ATV/r) is associated with clinical jaundice, which may affect ART adherence. However, the prevalence of clinical jaundice among people on ATV/r and its association with ART adherence is unknown in Uganda.

methodsWe conducted a cross-sectional study among 236 adult patients on ATV/r at the Infectious Disease Institute. Clinical jaundice was assessed by self-report and observation; ART adherence was measured using the 8-item Morisky scale.

resultsPeriod prevalence of clinical jaundice was 31.8%, while point prevalence was 21.1%. While 8.5% had poor adherence, clinical jaundice was a significant predictor of poor adherence (adjusted odds ratio = 3.03, 95% CI: 1.18-7.76, p = 0.021).

conclusionClinical jaundice is common among patients on ATV/r in Uganda and is associated with poor ART adherence. Strengthening pre-ATV/r (pre-switch) counselling and exploring safer regimen alternatives are required to improve outcomes.

Indexed as

Anti-HIV AgentsAtazanavir SulfateDrug MonitoringHIV InfectionsJaundiceMedication AdherenceAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceUgandaAnti-HIV AgentsAtazanavir SulfateAdherenceAntiretroviral therapyBoosted atazanavirClinical jaundiceHIV

Identifiers

PMID42401950
PMCPMC13625245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.